science pharmaceutical expo biotech jobs

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manna, P. P.
Right arrow Articles by Mohanakumar, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manna, P. P.
Right arrow Articles by Mohanakumar, T.
(Journal of Leukocyte Biology. 2002;72:312-320.)
© 2002 by Society for Leukocyte Biology

Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro

Partha P. Manna and T. Mohanakumar

Department of Surgery, Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri

Correspondence: T. Mohanakumar, Ph.D., Washington University School of Medicine, Department of Surgery and Pathology, Box-8109, 3328 CSRB, 660 S. Euclid Avenue, St. Louis, MO 63110. E-mail: kumart{at}msnotes.wustl.edu

Dendritic cells (DC) are an important subset of antigen-presenting cells characterized by their potent capacity to activate immunologically naïve T cells. However, their role in effector function in tumor resistance is less well characterized. We report here that activated human peripheral blood DC acquire a potent antitumor effect against breast cancer cell lines in vitro, leading to growth inhibition and apoptosis of the tumor cell. The antitumor effect of DC was augmented by proinflammatory stimuli induced by lipopolysaccharide (LPS) treatment. Tumor necrosis factor {alpha} (TNF-{alpha}) produced after DC activation was responsible for the antitumor activity of DC. Interferon-{gamma}, interleukin-15, or LPS treatment of DC markedly augmented the effector function of DC against most of the breast cells, indicating heterogeneity of the tumor and its susceptibility to cytokine-mediated damage. Treatment of LPS-activated DC or cell-free supernatant with anti-human TNF-{alpha} significantly reduces the antitumor effect against the tumor cells tested. These results suggest that in addition to their predominant role as immune regulatory cells, DC could serve as innate effector cells in tumor immunity.

Key Words: apoptosis • TNF-{alpha} • IFN-{gamma} • LPS




This article has been cited by other articles:


Home page
J. Immunol.Home page
C. Chauvin and R. Josien
Dendritic Cells as Killers: Mechanistic Aspects and Potential Roles
J. Immunol., July 1, 2008; 181(1): 11 - 16.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. M. Srivastava, C. Varalakshmi, and A. Khar
The Ischemia-Responsive Protein 94 (Irp94) Activates Dendritic Cells through NK Cell Receptor Protein-2/NK Group 2 Member D (NKR-P2/NKG2D) Leading to Their Maturation
J. Immunol., January 15, 2008; 180(2): 1117 - 1130.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Nicolas, D. Cathelin, N. Larmonier, J. Fraszczak, P.-E. Puig, A. Bouchot, A. Bateman, E. Solary, and B. Bonnotte
Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism
J. Immunol., July 15, 2007; 179(2): 812 - 818.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Trinite, C. Chauvin, H. Peche, C. Voisine, M. Heslan, and R. Josien
Immature CD4-CD103+ Rat Dendritic Cells Induce Rapid Caspase-Independent Apoptosis-Like Cell Death in Various Tumor and Nontumor Cells and Phagocytose Their Victims
J. Immunol., August 15, 2005; 175(4): 2408 - 2417.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Schmitz, S. Zhao, Y. Deuse, K. Schakel, R. Wehner, H. Wohner, K. Holig, F. Wienforth, A. Kiessling, M. Bornhauser, et al.
Tumoricidal Potential of Native Blood Dendritic Cells: Direct Tumor Cell Killing and Activation of NK Cell-Mediated Cytotoxicity
J. Immunol., April 1, 2005; 174(7): 4127 - 4134.
[Abstract] [Full Text] [PDF]